Sirolimus and Diffuse alveolar damage - a phase IV clinical study of FDA data

Summary:

Diffuse alveolar damage is reported as a side effect among people who take Sirolimus (sirolimus), especially for people who are female, 20-29 old, have been taking the drug for 6 - 12 months also take Tacrolimus, and have Acute graft versus host disease.

The phase IV clinical study analyzes which people have Diffuse alveolar damage when taking Sirolimus. It is created by eHealthMe based on reports of 11,812 people who have side effects when taking Sirolimus from the FDA, and is updated regularly.

What is Sirolimus?

Sirolimus has active ingredients of sirolimus. eHealthMe is studying from 11,823 Sirolimus users. Check the latest studies of Sirolimus.

What is Diffuse alveolar damage?

Diffuse alveolar damage (common manifestation of drug-induced lung injury) is found to be associated with 147 drugs and 360 conditions by eHealthMe. Check the latest studies of Diffuse alveolar damage.

On Jun, 17, 2026

11,812 people reported to have side effects when taking Sirolimus.
Among them, 16 people (0.14%) have Diffuse alveolar damage.

Could Sirolimus cause Diffuse alveolar damage?

Among these 16 people:

How long have people been on Sirolimus when they have Diffuse alveolar damage? *

What is the gender of people who have Diffuse alveolar damage when taking Sirolimus? *

female: 60 %
male: 40 %

What is the age of people who have Diffuse alveolar damage when taking Sirolimus? *

What are other drugs people take besides Sirolimus? *

What are other side effects people have besides Diffuse alveolar damage? *

Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 11 people, 68.75%
Pancreatitis (inflammation of pancreas): 7 people, 43.75%
Posterior Reversible Encephalopathy Syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss): 7 people, 43.75%
Polyomavirus-Associated Nephropathy (polyomavirus-associated kidney disease): 7 people, 43.75%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 7 people, 43.75%
High Blood Pressure: 7 people, 43.75%
Pulmonary Alveolar Haemorrhage (acute bleeding): 3 people, 18.75%
Pneumonia: 3 people, 18.75%
Pulmonary Haemorrhage (acute bleeding from the lung): 2 people, 12.50%
Granuloma (a small area of inflammation due to tissue injury): 2 people, 12.50%

What are the existing conditions these people have? *

Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 6 people, 37.50%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 6 people, 37.50%
Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 5 people, 31.25%
Immunodeficiency Disorders: 2 people, 12.50%
Squamous Cell Carcinoma Of Skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin): 1 person, 6.25%
Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 1 person, 6.25%
Acute Graft Versus Host Disease In Intestine (acute complication in intestine following an allogeneic tissue/blood transplant): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Sirolimus and have Diffuse alveolar damage?

- Check whether Diffuse alveolar damage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sirolimus:

Sirolimus (11,823 reports)

Browse all side effects of Sirolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diffuse alveolar damage:

Diffuse alveolar damage (147 drugs)

Browse all the conditions that are associated with Diffuse alveolar damage:

Diffuse alveolar damage (360 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sirolimus (the active ingredients of Sirolimus) and Sirolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.